Prescription digital therapeutics startup MedRhythms has entered into a licensing agreement with Biogen to develop and commercialize its MR-004 product, which aims to improve mobility for people with multiple sclerosis (MS).
Under the deal, MedRhythms would receive a $3 million upfront payment from Biogen, with the potential to earn up to $117.5 million if certain development and commercial...
Prescription digital therapeutics (PDTx) developer MedRhythms has added $25 million in Series B financing to its pot. Morningside Ventures and Advantage Capital co-led the raise, with participation from existing investor Werth Family Investment Associates as well.
The funding brings MedRhythms total amount raised to $34 million since its inception.
WHAT THEY DO
MedRhythms' PDTx combines sensors,...
The Digital Therapeutics Alliance, an industry group advocating for the adoption and understanding of evidence-based digital health treatments, has named its new Board of Directors. Representing handful of different digital therapeutics stakeholders, those named are set to hold their positions for a two-year period.
Along with Megan Coder, the group’s executive director, the board consists of:...
The past few days have seen new pivotal trial announcements from two startups eyeing FDA submissions for their digital health offerings.
On Thursday Cognoa unveiled an investigation for its pediatric development monitoring and diagnostic tool. This will be a multi-site, prospective, blinded, active comparator study of the tool, which is intended to support primary care autism diagnoses among...
